Evaluating the diagnostic and prognostic value of serum <scp>TuM2‐PK</scp>, <scp>NSE,</scp> and <scp>ProGRP</scp> in small cell lung cancer

Li, Li; Zhang, Qian; Wang, Yuchao; Xu, Chunhua

doi:10.1002/jcla.24865

Cited by 11 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have shown the high sensitivity of ProGRP in the diagnosis of SCLC, especially when utilized in combination with established tumor markers such as NSE and CYFRA21-1. 21,22 Combined detection typically enhanced overall diagnostic reliability compared to individual biomarkers due to the complementary nature of different indicators, a consensus supported by most of the previous reports. 23,24 Our study revealed that the combined detection of all six biomarkers yielded an impressive AUC ranging from 0.937 to 0.998 in diagnosing the three subtypes of LC, coupled with a high specificity of 98.0% (Table 3).…”

Section: Discussionmentioning

confidence: 72%

Human epididymal protein 4 and its combined detection show good diagnostic value in lung cancer: A retrospective study

Wu,

Chen,

Peng

et al. 2024

Int J Biol Markers

View full text Add to dashboard Cite

Objectives This study aimed to assess the diagnostic value of human epididymal protein 4 (HE4), a potential novel biomarker for lung cancer, and its combined detection with five other conventional biomarkers in lung cancer diagnosis and subtyping. Methods In this retrospective study, 115 lung cancer patients, 50 patients with benign pulmonary disease, and 50 healthy controls were included. Serum HE4, progastrin-releasing peptide (ProGRP), squamous cell carcinoma (SCC) antigen, cytokeratin-19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) were analyzed using the electrochemiluminescence immunoassay and chemiluminescence immunoassay. The receiver operating characteristic curve was performed to analyze the diagnostic efficacy of individual biomarkers in identifying both lung cancer and its histologic subtypes. Results All six biomarkers showed significantly elevated levels in the lung cancer group compared to both benign pulmonary disease and control groups ( P < 0.05). Among the biomarkers evaluated, HE4 exhibited the highest diagnostic performance for lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma with area under the curve (AUC) values of 0.921, 0.891, and 0.937, respectively. ProGRP was the optimal biomarker for small cell lung cancer with an AUC of 0.973. The combination of all six biomarkers yielded the largest AUCs in the diagnosis of lung cancer subtypes (0.937 for lung adenocarcinoma, 0.998 for lung squamous cell carcinoma, and 0.985 for small cell lung cancer). Furthermore, specific combinations, such as HE4 + CEA, HE4 + SCC, and ProGRP + HE4 + NSE, showed strong diagnostic performance in lung cancer. Conclusions HE4 and its combined detection held substantial clinical significance in the diagnosis of lung cancer and its histologic subtyping, especially for lung adenocarcinoma and lung squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 72%

Human epididymal protein 4 and its combined detection show good diagnostic value in lung cancer: A retrospective study

Wu,

Chen,

Peng

et al. 2024

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…In the study in which Li Li et al 20 analyzed the diagnostic and prognostic values of serum TuM2-PK, NSE and ProGRP values in small cell lung cancer, it was shown that M2-PK, NSE and ProGRP levels were higher than the control groups with benign lung disease and healthy control groups. Tu M2 PK sensitivity was found to be 82.35% and serum Tu M2 PK level may be an effective marker of small cell lung cancer and an independent prognostic factor for shorter survival.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of tumor m2-pyruvate kinase level in lung cancer and its relationship with tumor histological type

Aslan Kara,

Ortaköylü,

Uzun

2024

JOPIC

View full text Add to dashboard Cite

Aims: To investigate the diagnostic value of purivate kinase isoenzyme-M2 (M2-PK) levels and their relationship with tumor histological type in patients diagnosed with lung cancer. Methods: In this prospective study, 98 cases diagnosed with lung cancer (Study group) and 90 cases with lung cancer excluded (Control group) were included. The study group consisted of people over the age of 18 who had been diagnosed with lung cancer and had not received any treatment for the tumor. The control group consisted of 45 people who had been diagnosed with any lung disease but did not have lung cancer, and 45 of them were completely healthy people. Those with benign lung disease apart from lung cancer were named as control group-1 and healthy control group was named as control-group-2. Plasma samples with 5 cc of EDTA were taken from all subjects and these samples were quickly frozen at – 80 degrees and stored in this way until laboratory analysis could be performed. Commercial kit based on the sandwich ELISA principle (ScheBo Biotech Ag, Tumor M2-PK ELISA kit, Germany) was used to determine plasma M2-PK levels. The M2-PK values of the samples were calculated on the basis of the standard graph. Results: M2-PK levels were measured and compared in the lung cancer group, control group-1 with non-lung cancer lung disease and healthy control group-2. M2-PK levels were found to be significantly higher in the lung cancer group than in the control group-1 (p<0.0001) and control-group-2 (p<0.0001). When M2-PK levels were compared in all three groups, they were statistically significant in the lung cancer group (p<0.001). In our study, the diagnostic cut off value was found to be 8.9 IU/ml using ROC curve. At this cut-off value, plasma m2-pk level was calculated as 100% sensitivity and 97.8% specificity in showing lung cancer. When compared, there was no statistically significant difference between histopathological diagnoses, stage of the disease and M2-PK levels in the lung cancer group. Conclusion: As a result of this study, it has been shown that tumor M2-PK can be used in the differentiation of lung cancers from other benign lung lesions and as a marker in patients with suspected lung cancer.

show abstract

“…A study from 2023 from China reported that ProGRP levels in patients with SCLC were higher than in the healthy control group ( p < 0.05) and in the benign lung disease group ( p < 0.05); the sensitivity and specificity of ProGRP was estimated at 77.45% and 86.67%, respectively [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm

Rosiek

Kogut

Kos–Kudła

2023

Cancers

View full text Add to dashboard Cite

There is a lack of effective biomarkers for diagnosing lung neuroendocrine neoplasms (LNENs). A known small cell lung cancer (SCLC) biomarker is a pro-gastrin-releasing peptide (ProGRP), but not for all LNENs, especially for bronchopulmonary carcinoids. This study aimed to evaluate the diagnostic value of ProGRP and chromogranin A (CgA) in diagnosing LNENs. The ProGRP and CgA levels in 290 cases of LNENs and 54 healthy controls (HCs) were measured. The median ProGRP concentration in the group of LNEN patients was 136.4 pg/mL, higher than that of HCs at 6.5 pg/mL. Most of the LNEN cohort was well-differentiated tumors (typical and atypical carcinoids, n = 262, 91.7% of all LNENs). The sensitivity, specificity, and area under the curve (AUC) of ProGRP when distinguishing LNENs vs. HCs were 94.8%, 100%, and 0.995. CgA (AUC = 0.375) could not determine LNENs vs. HCs. Therefore, based on these results, ProGRP may be considered as an effective marker for diagnosing LNENs.

show abstract

Evaluating the diagnostic and prognostic value of serum TuM2‐PK, NSE, and ProGRP in small cell lung cancer

Cited by 11 publications

References 20 publications

Human epididymal protein 4 and its combined detection show good diagnostic value in lung cancer: A retrospective study

Human epididymal protein 4 and its combined detection show good diagnostic value in lung cancer: A retrospective study

Diagnostic value of tumor m2-pyruvate kinase level in lung cancer and its relationship with tumor histological type

Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm

Contact Info

Product

Resources

About